USPTO serial 79439298
RXILIENT
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- —
- Examiner
- HA, PAULINE T.
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 686 means your mark is published in the USPTO Official Gazette and in the 30-day opposition period. If no opposition is filed, prosecution typically continues toward registration or a Notice of Allowance. Monitor the opposition window. After it closes, watch for Notice of Allowance (intent-to-use) or registration (use-based).
Need help with RXILIENT?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Kassandra Rittmer
215 10th Street, Suite 1300Des Moines, IA 50309United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | pharmaceutical preparations and substances for the prevention of cancer; pharmaceutical preparations and substances for the treatment of cancer; pharmaceutical preparations and substances for use in oncology; pharmaceutical preparations for application to the skin for skin care and wounds; pharmaceutical preparations for health care for treatment and prevention of tumors, cancer, immune diseases, central nervous system diseases, eye diseases and conditions, and dermatological disorders; pharmaceutical preparations for ophthalmological use; pharmaceutical preparations for the topical treatment of dermatological disorders; pharmaceuticals for ophthalmological use; biochemicals preparations for pharmaceutical use for treatment and prevention of tumors, cancer, immune diseases, central nervous system diseases, eye diseases and conditions, and dermatological disorders; biopharmaceuticals for the treatment of cancer; pharmaceutical preparations for the treatment and prevention of eye diseases; pharmaceutical preparations for the treatment of eye diseases and conditions; preparations for the treatment of eye diseases; anti-cancer pharmaceutical preparations; veterinary pharmaceutical preparations in the form of capsules for the treatment and prevention of tumors, cancer, immune diseases, central nervous system diseases, eye diseases and conditions, and dermatological disorders; chemical preparations for pharmaceutical purposes for treatment and prevention of tumors, cancer, immune diseases, central nervous system diseases, eye diseases and conditions, and dermatological disorders; chemicals for pharmaceutical use for treatment and prevention of tumors, cancer, immune diseases, central nervous system diseases, eye diseases and conditions, and dermatological disorders; diagnostic agents for pharmaceutical use; drug delivery agents in the form of capsules that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; drug delivery agents consisting of compounds that facilitate the delivery of pharmaceutical preparations; intravenous fluids used for rehydration, nutrition and the delivery of pharmaceutical preparations; natural pharmaceutical preparations for treatment and prevention of tumors, cancer, immune diseases, central nervous system diseases, eye diseases and conditions, and dermatological disorders; chemical preparations for medical purposes for treatment and prevention of tumors, cancer, immune diseases, central nervous system diseases, eye diseases and conditions, and dermatological disorders; antibiotic dermatological products; antimicrobials for dermatologic use; barrier lotions for dermatological use; cortisone-based dermatological creams; creams for dermatological use; dermatologic preparations for medical purposes; dermatological pharmaceutical preparations; dermatological pharmaceutical products; external dermatological preparations; gels for dermatological use; hydrocortisone skin creams for dermatological use; injectable dermal fillers; medicated creams for treating dermatological conditions; medicated ointments for treating dermatological conditions; medicated lotions for treating dermatological conditions; pharmaceutical preparations for treating epidermal problems; pharmaceutical products for use in dermatology; skin patches for the transdermal delivery of pharmaceuticals for treatment and prevention of tumors, cancer, immune diseases, central nervous system diseases, eye diseases and conditions, and dermatological disorders; topical dermatological preparations for medical purposes; pharmaceutical moisturizers for skin and eyes; and diagnostic preparations for medical use. | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 6, 2026 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Oct 6, 2026 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Sep 30, 2026 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Sep 9, 2026 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Aug 4, 2026 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Aug 4, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Aug 4, 2026 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jul 21, 2026 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Jul 21, 2026 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jul 21, 2026 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jul 21, 2026 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Jul 21, 2026 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Jun 11, 2026 | RFNT | REFUSAL PROCESSED BY IB | — |
| May 20, 2026 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| May 20, 2026 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Apr 1, 2026 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Mar 31, 2026 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 25, 2026 | DOCK | ASSIGNED TO EXAMINER | — |
| Dec 19, 2025 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Dec 19, 2025 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Dec 18, 2025 | LIMI | LIMITATION FROM ORIGINAL APPLICATION ENTERED | — |
| Dec 11, 2025 | SDRC | SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB | — |